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Abstract
In the last years, especially thanks to a large diffusion of ultrasound-guided FNBs, a surprising increased incidence of
differentiated thyroid cancer (DTC), “small” tumors and microcarcinomas have been reported in the international
series. This led endocrinologists and surgeons to search for “tailored” and “less aggressive” therapeutic protocols
avoiding risky morbidity and useless “overtreatment”. Considering the most recent guidelines of referral endocrine
societies, we analyzed the role of routine or so-called prophylactic central compartment lymph node dissection
(RCLD), also considering its benefits and risks. Literature data showed that the debate is still open and the surgeons
are divided between proponents and opponents of its use. Even if lymph node metastases are commonly
observed, and in up to 90 % of DTC cases micrometastases are reported, the impact of lymphatic involvement on
long-term survival is subject to intensive research and the best indications of lymph node dissection are still
controversial. Identification of prognostic factors for central compartment metastases could assist surgeons in
determining whether to perform RLCD. Considering available evidence, a general agreement to definitely reserve
RCLD to “high-risk” cases was observed. More clinical researches, in order to identify risk factors of meaningful
predictive power and prospective long-term randomized trials, should be useful to validate this selective approach.
Keywords: Total thyroidectomy, Papillary thyroid cancer, Routine central lymph node dissection, Lymph node neck
dissection, Radioactive iodine ablation
Background
Differentiated thyroid cancer (DTC) is a relatively un-
common malignancy representing 1–2 % of all human
malignancies with a worldwide mean annual incidence
per 100,000 individuals ranging from 1.2 to 2.6 in men
and from 2.0 to 3.8 in women, with a surprising increase
in the last decades [1–5]. Papillary thyroid cancer (PTC)
is the most frequent variant, and recently in the USA, its
incidence is increased more than 240 % with 62.980
expected new cases in 2014. Thanks to US-guided
FNBs, more and more tumors less than 2 cm and
microcarcinomas were diagnosed [6–12]. According
to main international series, better oncological out-
comes are expected in these cases, and consequently,
a less “aggressive” and “tailored” multimodal approach
has been adopted to avoid a useless “overtreatment”
and risky morbidity. Finally, different scientific societies
suggested an accurate evaluation of laboratoristic,
instrumental, clinical and genetic risk factors before to
intimate a more “aggressive” therapeutic approach [13, 14].
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Considering the high rate of lymph node metastases rou-
tine or so-called prophylactic central compartment lymph
node dissection (RCLD) in clinically N0 patients is a matter
of intensive research and is still debated [15, 16]. Endocrine
surgeons, head and neck surgeons and otolaryngolo-
gists are divided between supporters and detractors of
its use. In the last decade, in order to reduce locore-
gional relapse (LR) rate and thyroglobulin (Tg) serum
levels, a trend toward routine dissection, avoiding radio-
active iodine (RAI), has been generally reported.
Nevertheless, lastly, considering evidence-based medi-
cine (EBM) data, several authors suggested its avoid-
ance in clinical practice reserving prophylactic
dissection in high-risk patients [17–20]. The absence
of macroscopic lymph node metastases node dissec-
tion might determine an overstaging of disease and a
risky overuse of RAI that is not associated to better
oncological outcomes in terms of LR and long-term
survival in every case. Moreover, a not negligible
morbidity should be taken into account.
So, in order to avoid risky “overtreatment” in low-risk
patients or at the same time underestimate the real
oncological status, identification of pre- and periopera-
tive risk factors of meaningful predictive power should
be considered subject to intensive research and of para-
mount interest.
Performing a literature review and considering the
available evidence, in an attempt to better clarify the
suitable indication and extension of routine central com-
partment neck dissection, we reviewed indications to
lymphatic dissection in the current management of
DTCs. Clinical experience, inhering the management of
thyroid cancer in the last two decades and of the endo-
crine and endocrine surgery centers participating in the
study, were also taken into account.
Review
Study design
LD, lateral or central LD, modified radical neck dissection,
RCLD, selective, prophylactic or therapeutic LD, DTC and
PTC were used as key words to perform a PubMed data-
base research. The most recent guidelines regarding neck
dissection for PTC according to the American Thyroid
Association (ATA), European Thyroid Association (ETA),
Unità operative di Endocrinochirurgia (UEC), American
Head and Neck Society and American Academy of
Otolaryngology-Head and Neck Surgery, Japanese Society
of Thyroid Surgeons and Japanese Association of
Endocrine Surgeons (JSTSJAES) and European Society
of Endocrine Surgeons (ESES) were also considered.
In particular, regarding terminology of cervical lymphatic
anatomy (neck levels) and classification of neck dissection,
the most recent ATA guidelines were considered [8]. LD
benefits and risks, available evidence, complications and
impact on locoregional recurrence rate and mortality were
also evaluated.
Risk factors
Researchers try to identify thyroid cancer predictive risk
factors, pre-existing concauses of cancer onset or cancer-
associated conditions that should be considered especially
in preoperative evaluation of uncertain neoplastic lesions
(Table 1). The most important environmental and exogen-
ous factors are X-rays and 131I exposure, iodine and endo-
crine disruptors, while the endogenous ones are gender
and age, TSH, autoimmunity, obesity and insulin resist-
ance, hereditary conditions and family history.
Exposure to head or neck radiation in childhood is a
proven risk factor correlated to the intensity of radiation
and the age of the child, increasing with larger doses
and with younger age at treatment [21]. Moreover, X-ray
and 131I exposure may increase thyroid risk cancer also
in adult as well as autoimmune thyroiditis or prolonged
iodine deficiency, associated to elevated TSH serum
levels [22–25].
The gender disparity in incidence, aggressiveness and
prognosis of thyroid cancer is well established. A pos-
sible role in the sex-related different biologic behavior
might be played by the difference in the estrogen recep-
tor subtypes expressed in tissue but the argument is still
subject to controversies and the substantial causes have
to be still clarified [26]. A family history of thyroid can-
cer is present in about 5 % of the patients and interest-
ing researches have been reported. Usually, the familial
non-medullary carcinoma is mostly of papillary histotype
more aggressive than the sporadic forms with an inci-
dence of 6.2–10.5 % and an autosomal, polygenic, dom-
inant transmission but with incomplete penetrance [1].
PTC may furthermore occur in patients with familial
adenomatous polyposis and its subtype Gardner’s syn-
drome, both sharing etiopathogenic defects in the gene
APC [27, 28]. A high risk of papillary or follicular
thyroid carcinoma has been also described in patients
with Cowden’s disease and in people affected by Carney
complex type I [1].
Table 1 Risk factors for thyroid cancer
Esogenous Endogenous
X-ray and 131I exposure
[21–25]
Gender (male) and age (<15 or >45 years)
[39–43]
Endocrine disruptors TSH [23]
Autoimmunity [22,24]
Obesity and insulin resistance [29–33]
Family history of thyroid cancer (5 %),
hereditary conditions (familial non-medullary
carcinoma, familial adenomatous polyposis, etc.)
[26–28]
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A higher BMI and incorrect eating habits, such as the
excessive use of butter, cheese, starches and smoked fish,
are moreover associated to an increased risk while a diet
rich in fruits and vegetables seems to play a protective
role [29–32]. Moreover, recent studies suggest the possi-
bility that insulin resistance and hyperinsulinemia, a
typical feature of obesity and metabolic syndrome, may
be a risk factor for thyroid cancer [5, 33].
The role of some environmental pollutants as endo-
crine disruptors interfering with hypothalamic-pituitary-
thyroid axis secretions is subject to intensive research
and definitive conclusions were not reported [5, 34].
Finally, an interesting paper demonstrated an increased
incidence of papillary thyroid microcarcinoma in Sicily,
especially in the volcanic area, where it was more ag-
gressive in young patients [35].
Prognostic factors: state of art
There is no consensus regarding RCLD in PTC patients,
and identification of prognostic factors for central lymph
node metastases (CLNM) could assist surgeons in deter-
mining whether this procedure should be performed.
Therefore, pre- and intraoperative risk factors for level
VI metastases are of paramount interest and subject to
intensive research.
Several papers yielded conflicting results due to
variations in the study settings and in the observed
population [36–38].
Factors increasing the risk of CLNM include the fol-
lowing: tumor size >1 cm, aggressive variants of PTC,
extra thyroidal extension, tumor multifocality, age >45
or <15 years, male gender, white race, familiality, BRAF
V600 mutation [39–41]. Nevertheless, literature results
are not conclusive and still matter of debate. As well,
recognized age has been undoubtedly reported to be a
risk factor. The cut-off of 45 years is widely used as a
clinical marker for prognosis [42]. In fact traditionally,
patients older than 45 years are more often associated
with poor prognosis and increased recurrence, as well as
frequently reported for child <15 years [43].
A recent meta-analysis has observed that age younger
than 45 years is a significant risk factor for CLNM in
CN0 patients [44].
Although the incidence of thyroid cancer is higher in
women, the rates of malignancy and mortality due to
thyroid cancer are higher in men [45]. So the male sex
can be considered as a risk factor [44].
Tumor size is another important factor in TNM
staging, and large tumors are more prone to be
aggressive [46]. The tumor size has been repeatedly
confirmed as an independent predictor of both patho-
logic and clinical outcomes. Lymph node metastasis is
known to increase with tumor size, and moreover, Jeong
et al. showed an association between large neoplasms
and LN metastases [47]. In their study, mean tumor
size was greater in N+ cases compared to N0 patients
(1.59 ± 1.03 vs 0.93 ± 0.62 cm; p < 0.001). Literature
meta-analysis confirmed that larger tumors (>1 cm)
were associated with an increased risk of CLNM [44].
Lim et al., in a previous study, had reported that
tumor size (>5 mm) was a significant predictive factor of
CLNM in PTC microcarcinoma [48]. Machens et al. also
had demonstrated that PTC microcarcinoma of >5 mm
were more associated with poor prognostic factors com-
pared with those of <5 mm [49].
BRAF mutations have been found in various cancers
including melanoma, colon cancer, and thyroid cancer,
and in PTCs BRAFV600E mutation, a T1799A point
mutation in the B-type Raf kinase gene is thought to be
the most common genetic alteration related to tumor
aggressiveness and poor prognosis [50–55].
Moreover, BRAFV600E mutation was independently
related to known unfavorable prognostic factors such as
extrathyroidal invasion, lymph node metastases, ad-
vanced tumor stage (III/IV) and aggressive subtypes. In
fact, it was associated to PTC recurrence, even in low-risk
groups [53]. Finally, in a retrospective multicenter study,
BRAFV600E mutation-positive patients experienced more
deaths per 1000 person-years than their wild-type coun-
terparts (11.80 vs 2.25, hazards ratio 1⁄4 3.53) [54].
A recent meta-analysis, including 20 studies and 9084
patients that had undergone thyroidectomy + prophylactic
central lymph node dissection (PCLND), extensively fo-
cused on the risk factors for central lymph node metasta-
sis (CLNM) in patients with clinically negative central
compartment lymph nodes [44]. As results, the fol-
lowing variables were associated with an increased risk:
age <45 years, male sex, multifocality, tumor size >2 cm
for PTC and >0.5 cm for papillary microcarcinoma, loca-
tion of primary tumor in the central area and low lobe,
lymphovascular invasion, capsular invasion and extrathyr-
oidal extension. Instead, bilateral tumors and lymphocytic
thyroiditis did not show association with increased risk of
CLNM in these patients. The authors concluded that
these factors should guide the application of PCLND in
patients with clinically negative central compartment
lymph nodes.
In conclusion, identification of PTC clinicopathologi-
cal risk factors is crucial to improve the accuracy of
recurrence rate estimates and to facilitate the calculation
of patient‐specific disease mortality rates. Furthermore,
it could allow a better selection of therapeutic protocol
facilitating modality of follow-up [56].
Lymph node dissection: definition and rationale of
modern trends
CLNM are very frequent while lateral ones are rare and
might be associated to a worse prognosis. In most cases,
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contralateral central or lateral spreading follows ipsilat-
eral metastases, but “skip lesions” may be observed in
about 10 % of patients, especially in superior pole
cancers. In clinically N0 patients, the most suitable dis-
section is still debated because of uncertain prognostic
value of micro and macro nodal metastases on onco-
logical outcomes. The obscure significance of node in-
volvement is the main cause of this unsolved issue.
Thyroid cancer represents a unique and atypical neo-
plasm mostly associated to a favorable prognosis. Dis-
similarly to all other cancers originating from different
anatomic districts—chest, gastrointestinal, reproductive
system….—in which unavoidably lymph node metastases
are associated to a worse prognosis, in DTC they are not
synonymous of more aggressive biological behavior
and are not associated to unfavorable outcomes.
Nevertheless, in clinically N+ patients, a higher rate
of persistent or recurrent disease is mostly reported,
and in “high-risk” cases, node metastases might affect
long-term survival [16, 57]. According to Smith et al.,
who reported an analysis of about 11,000 cases, in
clinically N+ patients >45 years lateral nodes are as-
sociated to a worse prognosis respect to younger pa-
tients with central compartment metastases [58].
Moreover, the surprisingly elevated incidence of
microscopically positive lymph nodes, their natural evo-
lution and their not frequent progression to a clinical re-
currence represent the second obscure phenomena that
should be clarified by more and more researches. All
therapeutic efforts in order to eradicate microscopic dis-
ease do not favorably modify just fair oncological out-
comes placing patients to risk of useless “overtreatment”
with long-term unfavorable side effects.
In clinical management of node metastases, several
oncological principles are well-known dogmas while
other ones are still debated. First of all, an accurate
staging is recommended but physical examination and
cervical ultrasound are still critical in the preoperative
work-up because in about one third of cases unexpected
node metastases are successively discovered. So an ac-
curate intraoperative inspection from hyoid bone to ster-
nal notch by an expert surgeon is mandatory to avoid
missing residual disease postoperatively associated to
higher Tg serum levels and recurrence rate [59]. Explicit
and clear communication between specialists about prior
operations (extent of disease and sublevels of dissection)
is very important to avoid risky interventions and facility
surgical management (scarred surgical bed). Until the
anatomic node classification and definition of neck dis-
section by American Society of Head and Neck Surgery
and successively by ATA [8], operative reports were un-
able to accurately describe lymphatic involvement and
extension of dissection performed. Consequently, retro-
spective analysis of surgical results was unreliable and
outcomes incomparable. Thanks to specific anatomic
landmarks, nodes were accurately divided into cervical
and mediastinal levels (I–VII) and moreover grouped
into central (I, VI and VII) and lateral neck compart-
ment (II–V). Central and lateral neck dissections were
described by a published consensus statement on the
terminology and classification [60, 61].
So neck dissection is nowadays performed by a stan-
dardized and widely diffuse surgical approach. Selective
lymph node dissection (central LD is its variant) intro-
duced by Ballantyne in 1980—consisting en bloc re-
moval of all lymphatic fibrous adipose tissue along with
specific fascial planes—or modified radical neck dissec-
tion (MRND) firstly described by Suarez-Bocca in
1967—en block removal of all neck levels (I–VII) with
respect of jugular vein, sternocleidomastoid muscle and
accessory spinal nerve—became the operations of choice
in DTC treatment. Radical neck dissection, associated to
higher morbidity and “berry picking” followed by higher
recurrence rate, are mostly contraindicated.
In case of clinical node involvement, a compartment-
oriented resection of the entire lymphatic basin—systematic
selective ipsilateral or bilateral, central or lateral dissection,
or mono or bilateral MRND—is recommended accord-
ing to risk categories in order to obtain a lower recur-
rence rate and a higher survival [62, 63]. In clinically
N+ “high-risk” patients, in the presence of more than five
metastatic lymph nodes or of one node greater than 3 cm
in diameter, a selective lateral dissection may be associated
to a central compartment one (levels III–IV) [64]. In
patients affected by lateral metastases, central and lat-
eral neck dissection is required (levels II, III, IV, VI),
reserving a bilateral dissection, in case of multiple
metastases, considering the elevated incidence of
contralateral central neck metastases demonstrated in
the surgical specimens.
Conversely, in the absence of involved nodes, the role
of prophylactic LD is still debated [65, 66]. According to
its proponents, RCLD, defined as complete excision of
the levels VI and VII (considering the recognized ana-
tomical continuity from neck and superior mediastinum)
might be safely performed avoiding to miss virulent
disease, allowing a better chance of cure with a low
morbidity, and reducing postoperative Tg serum levels
and recurrence risk. The following should be suggested:
considering higher morbidity of reoperations, removing
potential source of recurrence, improving diagnostic ac-
curacy, simplifying the follow-up and finally modifying
the indications to RAI [67–69]. Caliskan et al. suggested
that the central compartment dissection is technically
feasible and safe representing the best way to determine
node status for a more accurate staging and risk stratifi-
cation [69]. Nevertheless, it is generally associated with a
higher rate of transitory complications and according to
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Barczynski et al. and T.S. Wang et al., it is contraindi-
cated in low-volume centers [70, 71]. Higher morbidity
rate, the uncertain clinical significance of node involve-
ment, absence of proven benefits on survival, a conse-
quent up staging and finally a RAI overuse with
undesirable side effects such as nausea, vomiting,
ageusia, salivary gland swelling, sialoadenitis, xerostomia,
pulmonary fibrosis, dental caries and second primary
malignancies (0.5 %) are advocated against routine LD.
Moreover, a similar risk of local recurrence—0–9 %—was
reported in clinically N0 patients who undergone RCLD
or TT alone [8], differently from N+ cases (relapse rate up
to 40 %).
The most common questions are as follows: Does
RCLD reduce locoregional recurrence? Does it in-
crease morbidity? Does it increase the morbidity in
patients that have to be re-operated on the central
compartment? According to interesting meta-analysis
and evidence-based medicine (EBM) studies, RCLD
might reduce locoregional recurrence (level IV–V, no
recommendation), improve disease-free survival (grade C),
increase the number of patients with undetectable levels of
Tg (level IV, no recommendation) and increase permanent
hypoparathyroidism and recurrent nerve lesions (grade C).
It must be performed by experienced hands (C) [67, 72].
Finally, central compartment reoperations increase
permanent hypoparathyroidism and recurrent lesions.
Recently, Barczynski et al. stated that RCLD upstages
PTC patients determining risky overuse of RAI that is
not associated to a better outcome [70]. Nevertheless,
several authors demonstrated that most LN recur-
rences are in the lateral compartment (levels III–IV)
reducing the supposed RCLD benefits [73].
Moreover, micrometastases do not affect clinical
course and outcome of PTC patients [20]. In conclusion,
routine LD allows a better staging and RAI selection
reducing in some cases Tg serum level and recurrence
rate but nevertheless is associated to higher risk of
complications. According to literature data, Table 2 reports
proponents and opponents of prophylactic node dissection
testifying that the debate is still open.
In addition, analyzing the most recent series, a similar
recurrence rate was reported in patients undergone TT
alone or associated to routine LD, reducing presumed
advantages of prophylactic operations (Table 3).
The adoption of risk factors in stratifying patient
categories remains of paramount importance to avoid
useless RCLD. As reported above, age <45 years,
Table 2 Proponents and opponents of RCLD
Pros Cons
Y Ito et al. WJS 2006 DL Steward et al. Thyroid 2019
CL Lundgren et al. Cancer 2006 WT Shen et al. Surgery 2010
M Shindo et al. Arch OHN J 2006 AR Shaha et al. Cure Op Ot HNS 2011
M Sywak et al. Surgery 2006 MA Moreno et al. Thyroid 2012
ML White et al. WJS 2007 DE Gyorki et al. Ann Surf Oncol 2013
JL Roh et al. Ann Surg Onc 2008 G Conzo et al. Endocrine 2013
W Hu et al. AI Zheng 2008 K Zanocco et al. Surgery 2013
YI Son et al. Ann Surg Onc 2008 L Santini et al. Surgery 2014
N Palestini et al. Arch. Surg 2008 PG Calò et al. WJSO 2014
S Bonnet et al. ICEM 2009 P Miccoli et al. JCEM 2015
Y Giles et al. Surgery 2009
G Senyurek et al. Surgery 2009
BM Sadowski et al. Surgery 2009
YK So et al. Surgery 2010
TA Moo et al. WJS 2010
Sui-Zhou Xiao et al. WJS 2010
P Caglia et al. G. Chir. 2010
YS Lee et al. WJS 2010
M Barczyński et al. Br J Surg 2013
TS Wang et al. Ann Surf Onco 2013
Q Wang et al. Clin Transl Oncol 2014
P Summan et al. Surgery 2015
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multifocality, familiality, male sex, aggressive patho-
logical variants, BRAF V600 mutation and tumor size
larger than 1 cm are the main independent preoperative
variables. They should be considered in association with
extra capsular thyroid infiltration, positive margins, and
lymphovascular invasion that might be intra- or postop-
eratively acquired.
Therefore, different selecting criteria were suggested
to identify the best RLCD indications. Several surgeons
are in favor of its use in high-risk cases, in presence of
positive frozen section or biopsy-proven disease and in
lateral clinically node-positive patients. In addition,
ipsilateral routine dissection plus frozen section (and
eventually contralateral dissection) was recently intro-
duced considering a high morbidity rate of bilateral
procedure and that isolated contralateral LN metasta-
ses are exceptionally described. This tailored approach
showed similar staging ability to that observed after
bilateral RCLD and a lower morbidity rate similar to
that reported after TT alone. The main limit con-
sisted in overlooking contralateral metastases with a
higher recurrence rate [74].
In the absence of adequate statistical power to demon-
strate clear benefits on long-term outcomes, more pro-
spective clinical trials are needed.
The most recent ATA and UEC guidelines stated that
prophylactic LD could be considered in high-risk pa-
tients with advanced primary tumors and should be per-
formed by high-volume surgeons to avoid definitive
complications [62]. A reduced local recurrence rate and
a lower Tg serum level may be expected. The procedure
allows a better staging too [68], but a prospective
randomized study on RCLD role could be very expen-
sive and not readily feasible [75]. Revisiting the 2014
Japanese Society of Thyroid Surgeons and Japanese
Association of Endocrine Surgeons (JSTSJAES) guidelines,
it has been stated that in the absence of definitive data
about prophylactic CND in a large series of patients, its
indication depends on institutional policy and surgeons’
skill levels [76]. On the contrary, Consensus European
Society of Endocrine Surgeons (ESES) confirmed that
routine level VI prophylactic dissection should be risk
stratified in T3–T4 cases, in patients >45 or <15 years,
male patient, bilateral or multifocal tumors, lateral known
involved lymph nodes [77].
In our experience, a clinical retrospective study on 221
cases, TT followed by RAI administration and TSH sup-
pression therapy, guaranteed optimal long-term results,
with a low incidence of locoregional recurrence similar
to that reported in patients undergone TT alone [16].
Reoperations were usually not associated with higher
morbidity, especially performing unilateral dissection,
although hypoparathyroidism and unintentional recur-
rent laryngeal nerve injury have been observed in up to
14 and 9 % of patients, respectively [78].
In the absence of enlarged lymph node, and when
RAI administration is advisable (tumor >2 cm in a
male patient >50-year-old), routine lymph node dis-
section might be not indicated, while, in low-risk pa-
tients with tumors ≤1 cm, RCLD may discover
metastases requiring RAI ablation, modifying the
therapeutic protocol [68]. Nevertheless, in these pa-
tients, the RAI advantages remain to be proven.
Gyorki et al., in favor of therapeutic central neck dis-
section, in a recent assessment of clinical evidence,
hypothesized that node positivity, following prophylac-
tic dissection, may encourage administration of higher
doses of 131I without obvious benefit [79].
Finally, analyzing potential oncological benefits and
morbidity rate, routine dissection of level V (a/b) is still
a controversial topic, reserving its indication only to N+
cases [80].
Conclusions
In the treatment of DTC, considering a surprising
increasing rate of a precocious diagnosis of tumors less
than 2 cm and of microcarcinomas and the better
oncological outcomes expected, a “tailored” and “less
aggressive” multimodal therapeutic approach should be
suggested, to avoid unfavorable even if minimal morbid-
ity following a potential “overtreatment”.
In the absence of involved lymph nodes, prophylactic
dissection should be avoided, reserving RCLD to “high-
risk” patients to reduce the local recurrence rate. More
researches are needed in order to identify pre- and peri-
operative risk factors of predictive power useful in plan-
ning tailored therapeutic protocols.
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